Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway
ConclusionIn highly gemcitabine-resistant 231 cells, src inhibition can synergize with gemcitabine, reverse drug resistance, inhibit tumor growth/metastasis/stemness of cancer stem cells, possibly via the AKT/c-Jun pathway.
Source: PLoS One - Category: Biomedical Science Authors: Zhen-Hua Wu Source Type: research
More News: Biomedical Science | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Stem Cell Therapy | Stem Cells | Study